Description of criteria compatible with nodular regenerative hyperplasia (NRH) of the liver according to Wanless et al.<sup>[<sup>18</sup>]</sup> versus Jharap et al.
Bindia Jharap(Meander Medisch Centrum), Adriaan A. van Bodegraven(Zuyderland Medisch Centrum), K. H. de Boer Nanne, Joachim Diebold(University of Lucerne), Elisabeth Bloemena(Amsterdam Neuroscience), Dominique Wendum(Sorbonne Université), L. Emmanuelle, Verheij Joanne, Bedossa Pierre, Colombel Jean-Frédéric, A. Mieke Jonker(Refaja Ziekenhuis), Dirk P. van Asseldonk(Noordwest Ziekenhuisgroep), Fritz Wrba(University of Vienna), Walter Reinisch(Medical University of Vienna)
Cited by 0
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis
|Gastroenterology|2013|725
Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management
|Clinical and Translational Gastroenterology|2016|724